An ongoing requirement for MCL-1 in TEC survival. (A) Representative flow cytometry plots of MCL-1 expression in CD45⁻EpCAM⁺MHC II⁺ TECs isolated from grafts 5 days after the third dose of tamoxifen treatment. (B) Photos of experimental (denoted as “E” for Rosa^CreERT2Mcl1^lox/lox) and control (“C”) thymic lobes grafted under the renal capsule of C57BL/6-Ly5.1 males analyzed at indicated time points after 3 doses of tamoxifen treatment. (C) Total cell numbers recovered from grafts at the indicated time points after third dose of tamoxifen treatment. (D) Flow cytometry plots of MHC II and EpCAM gated on CD45⁻EpCAM⁺ TECs (representative of 3 experiments performed on 14-17 mice) and graphs of the number of CD45⁻EpCAM⁺MHC II⁺ TECs (middle) and proportion of CD45⁻EpCAM⁻ recovered from grafts 5 days after the third dose of tamoxifen treatment. Bars indicate mean ± SEM and groups were compared with a Student t test (2 sided, unpaired). ***P < .001; ****P < .0001. Controls include various combinations of genotypes (Rosa^Cre/CreMcl1^lox/+, Rosa^+/+Mcl1^lox/+, Rosa^+/+Mcl1^lox/lox).